Loading...
Publication
Inibidores de SGLT-2: uma utilização multifacetada e sempre em evolução
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| Documento em Acesso Embargado até dia 26-06-2028. Tente solicitar cópia ao autor carregando no ficheiro | 3.87 MB | Adobe PDF |
Authors
Advisor(s)
Abstract(s)
Esta tese aborda os inibidores SGLT2, uma classe farmacológica em constante evolução, destacando a sua multifacetada utilização no tratamento de diversas condições, com ênfase na insuficiência cardíaca. Inicialmente, são discutidos os conceitos fundamentais relacionados com a insuficiência cardíaca, incluindo sua definição, classificação, fisiopatologia, diagnóstico e opções terapêuticas atuais. Essa fundamentação permitirá compreender o papel emergente dos inibidores de SGLT2 no contexto clínico. De seguida, a tese explora esta classe farmacológica, abordando o seu desenvolvimento, mecanismos de ação, benefícios potenciais e efeitos adversos. São analisados especificamente os medicamentos empagloflozina, canagliflozina e dapagliflozina, destacando-se as suas contribuições na gestão da insuficiência cardíaca e outras patologias associadas. A revisão inclui também os principais estudos clínicos, como Empa-Reg Outcome, DAPA-HF, EMPEROR-Reduced e Canvas, que evidenciam a eficácia e segurança destes fármacos na prática clínica. Por fim, a tese discute estudos adicionais, como Credence e Dapa-CKD, que reforçam o potencial dos inibidores de SGLT2 em diferentes contextos de doença renal e cardiovascular. A análise evidencia a evolução do conhecimento sobre esses inibidores, consolidando o seu papel como uma ferramenta terapêutica multifacetada e em contínuo desenvolvimento, com impacto significativo na melhora dos resultados clínicos de pacientes com insuficiência cardíaca e outras condições associadas.
This thesis addresses SGLT2 inhibitors, a pharmacological class that is continuously evolving, highlighting their multifaceted use in the treatment of various conditions, with an emphasis on heart failure. Initially, fundamental concepts related to heart failure are discussed, including its definition, classification, pathophysiology, diagnosis, and current therapeutic options. This foundation helps to understand the emerging role of SGLT2 inhibitors in the clinical context. Subsequently, the thesis explores this pharmacological class, covering its development, mechanisms of action, potential benefits, and adverse effects. Specifically, the medications empagliflozin, canagliflozin, and dapagliflozin are analyzed, emphasizing their contributions to managing heart failure and other related pathologies. The review also includes key clinical studies such as Empa-Reg Outcome, DAPA-HF, EMPEROR-Reduced, and Canvas, which demonstrate the efficacy and safety of these drugs in clinical practice. Finally, the thesis discusses additional studies like Credence and Dapa-CKD, which reinforce the potential of SGLT2 inhibitors in different contexts of renal and cardiovascular disease. The analysis highlights the evolution of knowledge about these inhibitors, consolidating their role as a multifaceted and continuously developing therapeutic tool, with a significant impact on improving clinical outcomes for patients with heart failure and other associated conditions.
This thesis addresses SGLT2 inhibitors, a pharmacological class that is continuously evolving, highlighting their multifaceted use in the treatment of various conditions, with an emphasis on heart failure. Initially, fundamental concepts related to heart failure are discussed, including its definition, classification, pathophysiology, diagnosis, and current therapeutic options. This foundation helps to understand the emerging role of SGLT2 inhibitors in the clinical context. Subsequently, the thesis explores this pharmacological class, covering its development, mechanisms of action, potential benefits, and adverse effects. Specifically, the medications empagliflozin, canagliflozin, and dapagliflozin are analyzed, emphasizing their contributions to managing heart failure and other related pathologies. The review also includes key clinical studies such as Empa-Reg Outcome, DAPA-HF, EMPEROR-Reduced, and Canvas, which demonstrate the efficacy and safety of these drugs in clinical practice. Finally, the thesis discusses additional studies like Credence and Dapa-CKD, which reinforce the potential of SGLT2 inhibitors in different contexts of renal and cardiovascular disease. The analysis highlights the evolution of knowledge about these inhibitors, consolidating their role as a multifaceted and continuously developing therapeutic tool, with a significant impact on improving clinical outcomes for patients with heart failure and other associated conditions.
Description
Keywords
Insuficiência Cardíaca Inibidores do Co-Transportador de Sódio e Glicose 2 Diabetes Mellitus Hospitalização por Insuficiência Cardíaca Morte Cardiovascular Doença Renal Crónica Insuficiência Renal Heart Failure Sodium-Glucose Cotransporter 2 Inhibitors Hospitalization for Heart Failure Cardiovascular Death Chronic Kidney Disease Renal Failure